Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 23 of 23 publications.
Skip to main content
Colacci M, Raissi A, Ray P, Sholzberg M, Rothman KJ, Fralick M. Randomized controlled trials of switching to a new medication vs continuing a chronic medication may underestimate the risk of adverse events in those continuing because of asymmetric depletion of susceptibles. J Clin Epidemiol. 2024 Jun;170:111336. doi: 10.1016/j.jclinepi.2024.111336
Rebordosa C, Plana E, Rubino A, Aguado J, Martinez D, Lei A, Daoud S, Saigi-Morgui N, Perez-Gutthann S, Rivero-Ferrer E. Risk assessment of acute myocardial infarction and stroke associated with long-acting muscarinic antagonists, alone or in combination, versus long-acting beta2-agonists. Int J Chron Obstruct Pulmon Dis. 2022 Aug 2;17:1715-33. doi: 10.2147/COPD.S363997
Rebordosa C, Plana E, Rubino A, Aguado J, Lei A, Daoud S, Saigi-Morgui N, Perez-Gutthann S, Rivero-Ferrer E. A cohort study to evaluate the risk of hospitalisation for congestive heart failure associated with the use of aclidinium and other chronic obstructive pulmonary disease medications in the UK Clinical Practice Research Datalink. Int J Chron Obstruct Pulmon Dis. 2021 May 31;16:1461-75. doi: 10.2147/COPD.S301624
Pajouheshnia R, van Smeden M, Peelen LM, Groenwold RHH. How variation in predictor measurement affects the discriminative ability and transportability of a prediction model. J Clin Epidemiol. 2019 Jan;105:136-41. doi: 10.1016/j.jclinepi.2018.09.001
Donohue IF, Bollu VK, Stull DE, Nelson LM, Williams VS, Stensland MD, Hanania NA. Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial. Int J Chron Obstruct Pulmon Dis. 2018 Feb 5;13:499-508.
Wilson MR, Patel JG, Coleman A, McDade CL, Stanford RH, Earnshaw SR. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model. Int J Chron Obstruct Pulmon Dis. 2017 Mar 24;2017(12):997-1008.
Groenwold RHH, Moons KGM, Pajouheshnia R, Altman DG, Collins GS, Debray TPA, Reitsma JB, Riley RD, Peelen LM. Explicit inclusion of treatment in prognostic modeling was recommended in observational and randomized settings. J Clin Epidemiol. 2016 Oct;78:90-100. doi: 10.1016/j.jclinepi.2016.03.017
Boccia S, Rothman KJ, Panic N, Flacco ME, Rosso A, Pastorino R, Manzoli L, La Vecchia C, Villari P, Boffetta P, Ricciardi W, Ioannidis JP. Registration practices for observational studies on ClinicalTrials.gov indicated low adherence. J Clin Epidemiol. 2016 Feb;70:176-82. doi: 10.1016/j.jclinepi.2015.09.009
Martin SA, Coon CD, McLeod LD, Chandran A, Arnold LM. Evaluation of the fibromyalgia diagnostic screen in clinical practice. J Eval Clin Pract. 2014 Apr;20(2):158-65. doi: 10.1111/jep.12102
McKenna SP, Twiss J, Crawford SR, Oprandi NC, Tammaru M, Miravitlles M. The living with chronic obstructive pulmonary disease scale was successfully adapted for use in southern european (Italian and Spanish) and eastern european (Russian) cultures. J Clin Epidemiol. 2012 Aug;65(8):906-14.
Brown TM, Garg S, Chandran AB, McNett M, Silverman SL, Hadker N. The impact of 'best-practice' patient care in fibromyalgia on practice economics. J Eval Clin Pract. 2012 Aug 1;18(4):793-8.
Rycroft CE, Heyes A, Lanza L, Becker K. Epidemiology of chronic obstructive pulmonary disease: a literature review. Int J Chron Obstruct Pulmon Dis. 2012 Jul 1;7:457-94.
Stang A, Rothman KJ. That confounded P-value revisited. J Clin Epidemiol. 2011 Sep 1;64(9):1047-8.
Dalal AA, Demuro-Mercon C, Lewis S, Nelson L, Gilligan T, McLeod L. Validation of alternate modes of administration of the lung function questionnaire (LFQ) in subjects with smoking history. Int J Chron Obstruct Pulmon Dis. 2010 Dec 1;5:425-34.
Stuermer T, Rothman KJ, Avorn J. Pharmacoepidemiology and "in silico" drug evaluation: is there common ground? J Clin Epidemiol. 2008 Mar 1;61(3):205-6.
Drummond FJ, Sharp L, Carsin AE, Kelleher T, Comber H. Questionnaire order significantly increased response to a postal survey sent to primary care physicians. J Clin Epidemiol. 2008 Feb;61(2):177-85. doi: 10.1016/j.jclinepi.2007.04.012
Sturmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol. 2006 May 1;59(5):437-47.
Carnethon MR, Anthony MS, Cascio WE, Folsom AR, Rautaharju PM, Liao D, Evans GW, Heiss G. Prospective association between hormone replacement therapy, heart rate, and heart rate variability. The Atherosclerosis risk in communities study. J Clin Epidemiol. 2003 Jun;56(6):565-71.
Cella D, Eton DT, Faircloth DL, Bonomi P, Heyes AE, Silberman C, Wolf MK, Johnson DH. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy - Lung (FACT-L) questionnaire? Results from Eastern Cooperative Group (ECOG) Study 5592. J Clin Epidemiol. 2002 Mar;55(3):285-95.
Rothman KJ. My actual beliefs. J Clin Epidemiol. 2001 Dec 1;54(12):1275. doi: 10.1016/S0895-4356(01)00419-X
Rothman KJ. The ethics of research sponsorship. J Clin Epidemiol. 1991 Jan 1;44(Suppl 1):S25-8.
Lanes SF, Rothman KJ. Tampon absorbency, composition and oxygen content and risk of toxic shock syndrome. J Clin Epidemiol. 1990 Jan 1;43(12):1379-85.
Poole C, Rothman KJ. Epidemiologic science and public health policy. J Clin Epidemiol. 1990 Jan 1;43(11):1270-1. doi: 10.1016/0895-4356(90)90029-O